AUS
NZ
UK
CA
USA
IND
Highlights
- Record annual revenue reflects expanding international medical cannabis business.
- Balance sheet strengthens long-term financial flexibility.
- European acquisition broadens manufacturing and supply capabilities.
Aurora Cannabis strengthened its financial position through record annual performance, a balance sheet and expanded European manufacturing, reinforcing its international medical cannabis strategy.
Aurora Cannabis (TSX:ACB), a Canadian medical cannabis producer with an expanding international footprint, has entered the new fiscal year following record annual revenue, improved adjusted EBITDA and the elimination of outstanding debt. The acquisition of Safari Flower Company has also strengthened its European manufacturing network, supporting broader access across regulated medical markets. These developments have increased attention on Aurora within the Cannabis Stocks segment and among companies associated with the TSX Smallcap Index.
Record Financial Performance
Aurora Cannabis delivered its strongest annual financial performance, supported by continued expansion of its international medical cannabis business. The company reported record annual revenue alongside its highest adjusted EBITDA, reflecting the benefits of a strategy centred on premium medical cannabis products and disciplined operational management.
International medical cannabis remained the primary driver of business performance, with European markets contributing significantly to overall revenue. Growing patient access, expanding physician networks, and broader market availability supported continued demand across several international regions.
The latest results demonstrate the company's ongoing transition from restructuring efforts toward sustained operational execution and commercial expansion.
International Markets Drive Expansion
Aurora (TSX:ACB) has steadily increased its international presence by focusing on regulated medical cannabis stocks markets with established healthcare frameworks. Germany continues to represent one of the company's largest international markets, while additional business activity across the United Kingdom, Australia and other regions has diversified its revenue base.
The company's emphasis on international medical cannabis has enabled Aurora to reduce its dependence on the Canadian recreational market while strengthening relationships with healthcare providers and distributors abroad.
As more countries continue to expand regulated medical cannabis programmes, international operations remain an important component of Aurora's long-term business strategy.
Safari Flower Acquisition Strengthens Europe
Aurora recently completed the acquisition of Safari Flower Company, adding an EU-GMP certified cannabis manufacturing facility to its European operations.
The acquisition expands the company's manufacturing, packaging and distribution capabilities within Europe, helping improve supply chain efficiency across regulated medical cannabis stocksmarkets.
Having production infrastructure inside Europe supports faster access to regional markets while strengthening Aurora's ability to serve pharmacies and healthcare providers operating under European regulatory standards.
The acquisition also complements Aurora's broader strategy of expanding international operations through high-quality manufacturing and regulatory compliance.
Operational Discipline Supports Progress
Aurora's (TSX:ACB) recent performance reflects the operational changes implemented over several years. The company has streamlined cultivation activities, optimised production facilities and placed greater emphasis on higher-value medical cannabis products.
These initiatives have supported improved operational efficiency while helping strengthen profitability and business sustainability.
By focusing on disciplined cost management alongside international expansion, Aurora continues to build a more resilient operating model capable of supporting long-term development.
Medical Cannabis Remains Core Focus
Medical cannabis continues to form the foundation of Aurora's business strategy. The company develops and supplies products intended for patients under regulated healthcare systems across multiple countries.
This focus differentiates Aurora from businesses primarily serving recreational markets and allows the company to participate in healthcare systems where product quality, manufacturing standards and regulatory compliance remain critical.
Continued investment in medical cannabis research, product development and international distribution supports the company's long-term commercial objectives.
European Presence Continues Expanding
Europe remains one of the fastest-evolving regions for regulated medical cannabis. Aurora's established presence, combined with its newly expanded manufacturing capabilities, positions the company to support growing demand across the region.
The addition of local manufacturing infrastructure complements existing distribution channels while enhancing operational efficiency throughout European markets.
As regulatory frameworks continue evolving, companies with established production capabilities and recognised quality standards may be well positioned to support increasing patient access.
Focus Turns To The New Fiscal Year
Aurora Cannabis (TSX:ACB) is preparing for its upcoming Annual General Meeting, where management is expected to outline strategic priorities for the current fiscal year. Areas likely to remain in focus include international market expansion, capital allocation, manufacturing integration and continued operational execution.
Following a year marked by record financial performance, balance sheet improvement and expanded European operations, Aurora enters the new fiscal period with strengthened business fundamentals and a broader international platform.
